Literature DB >> 25176022

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.

Kasey Leger1, Tamra Slone, Matthew Lemler, David Leonard, Cindy Cochran, W Paul Bowman, Lisa Bashore, Naomi Winick.   

Abstract

BACKGROUND: Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤ 100 mg/m(2). This study was designed to assess LV function and key structural parameters following very low doses of anthracycline. PROCEDURE: Conventional 2-dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤ 100 mg/m(2), an average of 9.8 years from diagnosis. LV structural measurements were converted into Z-scores. The Z-score distributions were compared to those of the normal population. Diastolic and systolic function were quantified.
RESULTS: The cohort demonstrated a decreased posterior wall thickness (mean Z-score -1.01) and mildly decreased LV end diastolic (mean Z-score -0.85) and systolic (mean Z-score -0.84) dimensions compared to the normal population (P < 0.001). Further, 28% of patients (n = 25) had abnormal LV posterior wall thickness, ≥ 2 standard deviations below the mean (Z-score ≤ -2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF ≤ 28%.
CONCLUSIONS: A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiotoxicity; late effects of cancer treatment; pediatric oncology

Mesh:

Substances:

Year:  2014        PMID: 25176022     DOI: 10.1002/pbc.25206

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

1.  Towards a Model-Based Dose Recommendation for Doxorubicin in Children.

Authors:  Swantje Völler; Georg Hempel; Gudrun Würthwein; Alan V Boddy; Miriam Krischke; Nicolas André; Maurizio D'Incalci; Gianni Bisogno; Joachim Boos
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

Review 2.  Prevention of cardiotoxicity among survivors of childhood cancer.

Authors:  Kelley K Hutchins; Hani Siddeek; Vivian I Franco; Steven E Lipshultz
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

3.  Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.

Authors:  Nobutoshi Matsumura; Beshay N Zordoky; Ian M Robertson; Shereen M Hamza; Nirmal Parajuli; Carrie-Lynn M Soltys; Donna L Beker; Marianne K Grant; Maria Razzoli; Alessandro Bartolomucci; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

4.  Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors.

Authors:  William L Border; Ritu Sachdeva; Kayla L Stratton; Saro H Armenian; Aarti Bhat; David E Cox; Kasey J Leger; Wendy M Leisenring; Lillian R Meacham; Karim T Sadak; Shanthi Sivanandam; Paul C Nathan; Eric J Chow
Journal:  JACC CardioOncol       Date:  2020-03-17

Review 5.  Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.

Authors:  Becky Meiners; Chetan Shenoy; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2018-08-29       Impact factor: 5.027

6.  Cranial Irradiation in Childhood Acute Lymphoblastic Leukemia Is Related to Subclinical Left Ventricular Dysfunction and Reduced Large Artery Compliance in Cancer Survivors.

Authors:  Joanna Sulicka-Grodzicka; Bernadeta Chyrchel; Justyna Totoń-Żurańska; Ewelina Nowak; Paweł P Wołkow; Andrzej Surdacki; Tomasz Grodzicki
Journal:  J Clin Med       Date:  2019-11-13       Impact factor: 4.241

7.  Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study.

Authors:  Adriana Linares Ballesteros; Roy Sanguino Lobo; Juan Camilo Villada Valencia; Oscar Arévalo Leal; Diana Constanza Plazas Hernández; Nelson Aponte Barrios; Iván Perdomo Ramírez
Journal:  Colomb Med (Cali)       Date:  2021-02-15

Review 8.  Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.

Authors:  Bin Bin Wu; Kam Tong Leung; Ellen Ngar-Yun Poon
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

9.  Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.

Authors:  Michelle A T Hildebrandt; Monica Reyes; Xifeng Wu; Xia Pu; Kara A Thompson; Jianzhong Ma; Andrew P Landstrom; Alanna C Morrison; Joann L Ater
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

10.  Cardiac Surveillance for Early Detection of Late Subclinical Cardiac Dysfunction in Childhood Cancer Survivors After Anthracycline Therapy.

Authors:  Rosaria Sofia; Veronica Melita; Antonio De Vita; Antonio Ruggiero; Alberto Romano; Giorgio Attinà; Lisa Birritella; Priscilla Lamendola; Antonella Lombardo; Gaetano Antonio Lanza; Angelica Bibiana Delogu
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.